BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 9506355)

  • 21. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy.
    Kapp KS; Kapp DS; Poschauko J; Stücklschweiger GF; Hackl A; Pickel H; Petru E; Winter R
    Gynecol Oncol; 1999 Sep; 74(3):400-7. PubMed ID: 10479500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A; Sevelda P
    Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
    Karam AK; Santillan A; Bristow RE; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Li AJ
    Gynecol Oncol; 2007 Feb; 104(2):377-80. PubMed ID: 17014899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum].
    Ivanov S; Ivanov S
    Akush Ginekol (Sofiia); 2004; 43(5):36-8. PubMed ID: 15518283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors predicting recurrence in borderline ovarian tumors.
    Wu TI; Lee CL; Wu MY; Hsueh S; Huang KG; Yeh CJ; Lai CH
    Gynecol Oncol; 2009 Aug; 114(2):237-41. PubMed ID: 19481786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
    Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy.
    Ødegaard E; Staff AC; Langebrekke A; Engh V; Onsrud M
    Acta Obstet Gynecol Scand; 2007; 86(5):620-6. PubMed ID: 17464594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.